24.4 C
New York
Tuesday, August 16, 2022

Why is Capricor Therapeutics, Inc. (CAPR) stock Popping High Today?

Capricor Therapeutics, Inc. (CAPR) stock popped high today after it announced positive final data from its Phase 2 HOPE-2 Trial. CAPR stock price saw a push of 16.53% to reach $5.85 a share as of this writing. The stock went up in the previous trade by 3.29% at closing.

Capricor Therapeutics, Inc is the biotech stock that develops transformative cell- and exosome-based therapeutics to treat broad-spectrum diseases. Its lead product candidate is CAP-1002 which has now completed phase 2 trial to treat patients with late-stage Duchenne muscular dystrophy. Let’s dig in to explore more of it.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


What’s Happening?

Capricor therapeutics today released positive final data from the HOPE-2 clinical trial. In this trial, the Capricor study team was treating patients with advanced-stage Duchenne muscular dystrophy by using its lead product candidate CAP-1002. The trial met primary as well as other cardiac and skeletal endpoints. CAPR stock conducted the trial at nine sites in the United States. The study team analyzed the data of 20 patients and 80% of them were non-ambulant. Final data analysis suggested that young men with advanced DMD after getting four doses of CAP-1002 showed cardiac and skeletal improvements.

Financial View of CAPR stock in Q2,2021:

  • In the second quarter of 2021 ended June 30, Capricor stock generated $200,000 in revenue. This compares to $50,000 revenue in the same tenure of the previous year. The primary sources of revenue for the CAPR stock are collaborative payments from grant awards and clinical trial arrangements.
  • Operating expenses for the CAPR stock reached $5.3 million in the three months ended June 30, 2021. For the previous year’s same quarter, operating expenses were $3.5 million.
  • CAPR stock suffered a net loss of $4.7 million or $0.21 per share in the second quarter of 2021. The per-share net loss decreased as the previous year’s same quarter net loss was $0.23 per share.
  • By the end of the second quarter of 2021, CAPR stock had $38.1 million in cash and cash equivalents as compared to $32.7 million as of December 31, 2020.
  • Capricor stock generated $1.0 million in net proceeds via the issuance of its common stock at $5.41 per share average price in the at-the-market offering program.

Wrap Up:

Positive Final Data From its Phase 2 HOPE-2 Trial resulted in a significant increase in the per-share price of Capricor stock. The sentiment is positive, and investors expect that this development of CAPR stock will have long-term positive effects. Moreover, the management of Capricor stock expects that its cash in hand is sufficient to support operations for next two years.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2887

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

DOWNLOAD FREE EBOOK

BEST INFLATION STOCKS 2022

We put together a list of the best stocks that

we think can explode over the next 12 months.

2888

SPECIAL GIFT

2889
2890
2891

  What you will Get ?

   Best Inflation

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

DOWNLOAD FREE EBOOK

BEST GROWTH STOCKS 2022

We put together a list of the best stocks that we

think can explode over the next 12 months.

2899

SPECIAL GIFT

2900
2901
2902

  What you will Get ?

   Best Growth

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

2903

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

2915

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

2839

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam